Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID06134232

An Open-Label Multicenter Study of Men With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE and Boosted With One Sipuleucel-T Infusion to Measure Immune Response

Led by Dendreon · Updated on 2025-08-27

400

Participants Needed

31

Research Sites

26 weeks

Total Duration

On this page

Sponsors

D

Dendreon

Lead Sponsor

W

WCG IRB

Collaborating Sponsor

AI-Summary

What this Trial Is About

This trial focuses on men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously been treated with PROVENGE4 immunotherapy. The study aims to investigate changes in immune responses following a booster dose of sipuleucel-T, an immunotherapy treatment. The trial is a phase 2, multicenter, open-label study designed to better understand immune boost responses in this patient group. Participants who have completed their initial treatment with PROVENGE4 will be randomly assigned to one of two groups: one group will receive a single booster infusion of sipuleucel-T approximately 6 to 9 months after their initial treatment, while the other group will not receive any additional intervention. The sipuleucel-T is delivered as an intravenous infusion. Both groups will be monitored according to the study schedule. Throughout the study, participants will undergo evaluations to measure immune responses to specific prostate cancer antigens after the booster infusion. Researchers will also monitor adverse events and overall survival over a 5-year period. The study involves regular follow-up visits to assess safety and immune activity, with total participation lasting up to five years after treatment.

CONDITIONS

Brief Title

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male participants aged 18 years or older
  • Clinically indicated for treatment with PROVENGE4 for asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer
  • Have qualified and received all three infusions of PROVENGE4 prior to randomization
  • Provided written informed consent before study procedures
  • Estimated life expectancy of 12 months or more
Not Eligible

You will not qualify if you...

  • Not clinically indicated for PROVENGE4 treatment for metastatic castrate-resistant prostate cancer
  • Need for systemic chronic immunosuppressive therapy, including antitumor necrosis factor alpha monoclonal antibodies, glucocorticoids, systemic steroids, blood products, GM-CSF, or granulocyte colony-stimulating factor (G-CSF), any vaccinations, or experimental therapies
  • Uncontrolled or active illness such as ongoing infections or psychiatric conditions that limit compliance with study requirements
  • Currently on experimental or investigational therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single infusion at 6 to 9 months post initial treatment

Participants receive a single infusion of sipuleucel-T as a booster treatment 6 to 9 months after completing their initial PROVENGE® immunotherapy course.

1 infusion visit (in-person)

Follow-up

Duration - Up to 5 years

Participants are monitored for immune response, adverse events, and overall survival for up to 5 years after treatment.

Regular follow-up visits as described in study schedule

Trial Site Locations

Total: 31 locations

1

Arizona Urology Specialists

Tuscon, Arizona, United States, 85741

Actively Recruiting

2

City of Hope - National Medical Center

Duarte, California, United States, 91010

Actively Recruiting

3

Urology Associates of Central California Medical Group

Fresno, California, United States, 93720

Actively Recruiting

4

Unio Health Partners - Genesis Research, LLC

San Diego, California, United States, 92123

Actively Recruiting

5

Colorado Urology

Lakewood, Colorado, United States, 80228

Actively Recruiting

6

Advanced Urology Institute

Daytona Beach, Florida, United States, 32114

Actively Recruiting

7

Advanced Urology Institute

Largo, Florida, United States, 33771

Actively Recruiting

8

Advanced Urology Institute

Ocala, Florida, United States, 34471

Actively Recruiting

9

Florida Urology Partners

Riverview, Florida, United States, 33578

Actively Recruiting

10

Associated Urological Specialists

Chicago Ridge, Illinois, United States, 60415

Active, Not Recruiting

11

UroPartners

Glenview, Illinois, United States, 60026

Actively Recruiting

12

Advanced Urology Associates

New Lenox, Illinois, United States, 60451

Actively Recruiting

13

Urology of Indiana

Carmel, Indiana, United States, 46032

Actively Recruiting

14

First Urology

Jeffersonville, Indiana, United States, 47130

Actively Recruiting

15

Urologic Specialists of Northwest Indiana

Merrillville, Indiana, United States, 46410

Actively Recruiting

16

Chesapeake Urology Research Associates

Towson, Maryland, United States, 21204

Actively Recruiting

17

Michigan Institute of Urology

Troy, Michigan, United States, 48084

Actively Recruiting

18

Specialty Clinical Research of St. Louis

St Louis, Missouri, United States, 63141

Actively Recruiting

19

Integrated Medical Professionals

North Hills, New York, United States, 11040

Actively Recruiting

20

Associated Medical Professionals of NY

Syracuse, New York, United States, 13210

Actively Recruiting

21

Associated Urologists of North Carolina

Raleigh, North Carolina, United States, 27612

Actively Recruiting

22

The Urology Group

Cincinnati, Ohio, United States, 45212

Actively Recruiting

23

Central Ohio Urology Group

Gahanna, Ohio, United States, 43230

Actively Recruiting

24

Oregon Urology Institute

Springfield, Oregon, United States, 97477

Actively Recruiting

25

MidLantic Urology

Bala-Cynwyd, Pennsylvania, United States, 19004

Actively Recruiting

26

Keystone Urology Specialists

Lancaster, Pennsylvania, United States, 17604

Actively Recruiting

27

Lowcountry Urology Institute

Charleston, South Carolina, United States, 29406

Actively Recruiting

28

Carolina Urologic Research Center, LLC

Myrtle Beach, South Carolina, United States, 29572

Actively Recruiting

29

Urology Associates of Nashville

Nashville, Tennessee, United States, 37209

Actively Recruiting

30

Urology of Virginia

Virginia Beach, Virginia, United States, 23462

Actively Recruiting

31

Spokane Urology

Spokane, Washington, United States, 99202

Actively Recruiting

Loading map...

Research Team

M

Margaret Warner-Lubin

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Multicenter, Open-Label Phase II Study to Evaluate the Saf...

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Actively Recruiting

24 locations

A Phase 1a, Dose Escalation, Safety and Tolerability Study o...

Ovarian Cancer, Epithelial

Actively Recruiting

17 locations

MK-5684-004: A Randomized Study Comparing Opevesostat Plus H...

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Actively Recruiting

327 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here